Mots - the commentary with the half yearly report on 25/2/16 seems to be a bit contradictory to the update release on 27/1/16 - "The Company believes that there remains a vital role for ATC in the treatment of resistant patients and that it has significant potential to be a valuable new treatment for HIV as it addresses those pivotal issues which are unmet for many experienced HIV-infected patients. Accordingly, the directors will continue to review all options and make every effort to realise the value in ATC. Similarly, the directors consider that there is potential in the Company’s suite of HIV Integrase compounds and will actively search for co-development partners." I don't think we really know what business we are in.
AVX Price at posting:
3.3¢ Sentiment: Hold Disclosure: Held
